Skip to main content
NMTC
NASDAQ Industrial Applications And Services

NeuroOne Medical Technologies Announces CFO Retirement and Internal Succession

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.8
Mkt Cap
$39.71M
52W Low
$3.274
52W High
$6.96
52W Position info
47% above low
Off High info
31% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NMTC sits 47% above its 52-week low of $3.274.

Summary

NeuroOne Medical Technologies announced the retirement of its CFO, Ronald McClurg, and the appointment of current COO Christopher Volker as his successor, effective July 1, 2026, with a transition period.


Key Events · Executive and Board Changes · NMTC

  • CFO Ronald McClurg to Retire

    Ronald McClurg notified the company of his intention to retire as Chief Financial Officer, effective June 30, 2026. He will remain as a Senior Advisor until December 31, 2026, to ensure a smooth transition.

  • COO Christopher Volker Appointed New CFO

    Christopher Volker, the company's current Chief Operating Officer, will succeed Mr. McClurg as Chief Financial Officer, effective July 1, 2026. Mr. Volker has extensive experience in the medtech industry and corporate finance.

  • Transition Agreement Executed

    A Transition and Release Agreement was entered into with Mr. McClurg, dated April 28, 2026, outlining his continued salary and benefits until his retirement date in exchange for a general release of claims and customary restrictive covenants.


Analysis · NMTC · Industrial Applications And Services

This filing details a planned leadership transition in a critical financial role for NeuroOne Medical Technologies. The retirement of the current CFO, Ronald McClurg, is being managed with a transition period, and the appointment of Christopher Volker, the current COO, as his successor provides continuity and leverages internal talent. Given the company's recent disclosure of a going concern warning, Nasdaq delisting risk, and material weakness in internal controls, a stable and experienced financial leadership team is paramount. Mr. Volker's background in medtech, corporate finance, and investment banking is highly relevant to navigating the company's financial challenges. This orderly succession helps mitigate potential instability during a precarious period.

At the time of this filing, NMTC was trading at $4.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $3.27 to $6.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NMTC - Latest Insights

NMTC
Jun 12, 2026, 4:45 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.24
Real-time Price: $1.91 info
Change: -$1.33 (-41%) info
Market Cap: $16.536M info
NMTC
Jun 12, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.24
Real-time Price: $1.91 info
Change: -$1.33 (-41%) info
Market Cap: $16.536M info
NMTC
Jun 12, 2026, 4:32 PM EDT
Filing Type: 10-Q/A
Importance Score:
9
Price at Filing: $3.24
Real-time Price: $1.91 info
Change: -$1.33 (-41%) info
Market Cap: $16.536M info
NMTC
May 22, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.72
Real-time Price: $1.91 info
Change: -$1.81 (-49%) info
Market Cap: $16.536M info
NMTC
May 12, 2026, 8:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $1.91 info
Change: -$2.19 (-53%) info
Market Cap: $16.536M info